Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres ; day:2 ; month:8 ; year:2024 ; pages:1-8
Internal and emergency medicine ; (2.8.2024), 1-8
- Urheber
-
Quartuccio, Luca
Treppo, Elena
Martino, Maria De
Pillon, Maria
Perniola, Simone
Bruno, Dario
Isola, Miriam
Gremese, Elisa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11739-024-03722-4
- URN
-
urn:nbn:de:101:1-2410242115135.470230798343
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Quartuccio, Luca
- Treppo, Elena
- Martino, Maria De
- Pillon, Maria
- Perniola, Simone
- Bruno, Dario
- Isola, Miriam
- Gremese, Elisa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
Vision loss in patients with giant cell arteritis treated with tocilizumab
Tocilizumab for relapsing and remitting giant cell arteritis: a case series
Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis